Oncimmune announced that it has been awarded the Queen’s Award for Enterprise 2022 in the innovation category, endorsing Oncimmune as a leading developer of applied immunodiagnostics for the early detection of disease, drug discovery and development in immuno-oncology, autoimune and infectious diseases.
The Queen’s Award for Enterprise 2022 acknowledges the innovation behind Oncimmune’s immunodiagnostic and discovery technology. This started with EarlyCDT, a blood test which can help identify cancer on average four years earlier than current standard clinical diagnosis, and continues today through Oncimmune’s ImmunoINSIGHTS autoantibody biomarker profiling platform, which enables life science organisations to advance their clinical trials with biomarker insights leading to more effective targeting as well as safer treatments for patients.
The Queen’s award for Entreprise Magazine